<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this study we compared the ability of phenytoin, a microsomal enzyme inducer, to raise plasma <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>) levels in normolipidemic subjects and patients with primary <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In healthy control subjects, phenytoin caused a dose-dependent increase of plasma <z:chebi fb="17" ids="39025">HDL</z:chebi>, HDL2, and HDL3 cholesterol levels, up to 40% to 50% </plain></SENT>
<SENT sid="2" pm="."><plain>Minor changes were recorded in the plasma concentrations of <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> (apo) A-I and apo A-II; the plasma level of the cholesteryl <z:chebi fb="21" ids="35701">ester</z:chebi> transfer protein (CETP) decreased by 42% </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, none of the patients with <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e> had changes in plasma <z:chebi fb="17" ids="39025">HDL</z:chebi>, HDL2, or HDL3 cholesterol, apo A-I, apo A-II, or CETP levels </plain></SENT>
<SENT sid="4" pm="."><plain>These findings indicate that microsomal enzyme inducers are unsuitable to increase plasma <z:chebi fb="17" ids="39025">HDL</z:chebi> levels in high-risk patients with primary <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e>, and they disclose a new mechanism, that is, decreased CETP-mediated transfer of cholesterol out of <z:chebi fb="17" ids="39025">HDL</z:chebi>, for the <z:chebi fb="17" ids="39025">HDL</z:chebi>-raising effect of microsomal enzyme inducers in healthy individuals </plain></SENT>
</text></document>